lcl-161
Small moleculeexperimental
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT01098838)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(C(=O)c2ccc(F)cc2)cs1)C1CCCCC1- Mol. weight
- 500.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2431768 ↗
Also known as
- lcl-161
- lcl-161
- lcl-161
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02890069 | Phase 1 | Oct 14, 2016 | Novartis |
| NCT02649673 | Phase 1/Phase 2 (Phase 2) | Mar 23, 2016 | Novartis, SCRI Development Innovations |
| NCT02098161 | Phase 2 | Dec 1, 2014 | Novartis, University of Texas at Houston |
| NCT01934634 | Phase 1 | Mar 1, 2014 | Delta Clinical Research, LLC, Novartis, US Oncology |
| NCT01955434 | Phase 2 | Nov 1, 2013 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01968915 | Phase 1 | Nov 1, 2013 | Novartis |
| NCT01617668 | Phase 2 | Aug 1, 2012 | Novartis |
| NCT01240655 | Phase 1 | Apr 1, 2011 | Novartis |
| NCT01098838 | Phase 1 | Nov 1, 2008 | Novartis |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 8 | 5 | 2 | 2008 |
| Delta Clinical Research, LLC | For profit | 1 | 0 | 1 | 2014 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| SCRI Development Innovations | For profit | 1 | 1 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2014 |
| US Oncology | For profit | 1 | 1 | 1 | 2014 |
7 organizations
Page 1 / 1